JACARANDA BIOSCIENCES, INC.

Biotech · Private

Small molecule therapeutics (JBI-015, JBI-016, JBI-028) targeting the Unfolded Protein Response pathway to treat noise-induced hearing loss

Grants
$2.2M
3 awards
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
3
0 granted · 3 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantDepartment of Health and Human Services · Phase I · eiF2B Activators to Treat Noise-Induced Hearing Loss$299,999
Federal grantDepartment of Health and Human Services · Phase I · Development of UPR-Targeted Treatment for Cisplatin-Induced Ototoxicity.$304,762
Federal grantDepartment of Health and Human Services · Phase II · eiF2B Activators to Treat Noise-Induced Hearing Loss$1,554,254
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
3182BIOMAGNETIC SOLUTIONS, LLC——
3183REVIVO THERAPEUTICS, INC.——
3184SECRETORY IGA, INC.——
3185JACARANDA BIOSCIENCES, INC.——
3186TenSixteen Bio——
3187PARTEK, INC.——
3188SYNTHOMICS, INC.——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 0 granted of 3
  • Upr Modulators To Treat Hearing Lossapplication
  • Upr Modulators To Treat Hearing Lossapplication
  • Upr Modulators To Treat Hearing Lossapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.